Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.

Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, Tucker J, Tsang KY, Schlom J, Palena C.

Clin Cancer Res. 2012 Jul 15;18(14):3868-79. doi: 10.1158/1078-0432.CCR-11-3211. Epub 2012 May 18.

2.

Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma.

Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, Takenoyama M, Maehara Y.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S509-16. doi: 10.1245/s10434-013-2914-9. Epub 2013 Mar 1.

PMID:
23456319
3.

Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.

Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C.

Semin Oncol. 2012 Jun;39(3):358-66. doi: 10.1053/j.seminoncol.2012.02.005. Review.

4.

The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.

Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C.

J Clin Invest. 2010 Feb;120(2):533-44. doi: 10.1172/JCI38379. Epub 2010 Jan 11.

5.

T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma.

Imajyo I, Sugiura T, Kobayashi Y, Shimoda M, Ishii K, Akimoto N, Yoshihama N, Kobayashi I, Mori Y.

Int J Oncol. 2012 Dec;41(6):1985-95. doi: 10.3892/ijo.2012.1673. Epub 2012 Oct 17.

6.

Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.

Xu K, Liu B, Liu Y.

Mol Med Rep. 2015 Jul;12(1):995-1001. doi: 10.3892/mmr.2015.3348. Epub 2015 Feb 13.

7.

The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells.

Shimoda M, Sugiura T, Imajyo I, Ishii K, Chigita S, Seki K, Kobayashi Y, Shirasuna K.

BMC Cancer. 2012 Aug 29;12:377. doi: 10.1186/1471-2407-12-377.

8.

An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype.

Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C.

Mol Cancer Ther. 2013 Sep;12(9):1805-15. doi: 10.1158/1535-7163.MCT-12-1007. Epub 2013 Jun 19.

9.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

10.

The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.

Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J.

Clin Cancer Res. 2007 Apr 15;13(8):2471-8.

11.

T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines.

Chen S, Jiao J, Jiang D, Wan Z, Li L, Li K, Xu L, Zhou Z, Xu W, Xiao J.

Tumour Biol. 2015 Aug;36(8):5881-90. doi: 10.1007/s13277-015-3260-2. Epub 2015 Mar 6.

PMID:
25744730
12.
13.

T-box transcription factor brachyury promotes tumor cell invasion and metastasis in non-small cell lung cancer via upregulation of matrix metalloproteinase 12.

Wan Z, Jiang D, Chen S, Jiao J, Ji L, Shah AS, Wei H, Yang X, Li X, Wang Y, Xiao J.

Oncol Rep. 2016 Jul;36(1):306-14. doi: 10.3892/or.2016.4792. Epub 2016 May 9.

PMID:
27176766
14.

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.

15.

Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle.

Kobayashi Y, Sugiura T, Imajyo I, Shimoda M, Ishii K, Akimoto N, Yoshihama N, Mori Y.

Int J Oncol. 2014 Apr;44(4):1107-17. doi: 10.3892/ijo.2014.2292. Epub 2014 Feb 6.

16.

MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A.

Mol Cancer Ther. 2014 Feb;13(2):444-53. doi: 10.1158/1535-7163.MCT-13-0448. Epub 2013 Nov 20.

17.

SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.

Li K, Ying M, Feng D, Chen Y, Wang J, Wang Y.

Oncol Rep. 2016 Apr;35(4):2405-12. doi: 10.3892/or.2016.4564. Epub 2016 Jan 15.

PMID:
26781859
18.

The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.

Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C.

Cell Death Dis. 2013 Jun 20;4:e682. doi: 10.1038/cddis.2013.208.

19.

The T-box transcription factor Brachyury promotes renal interstitial fibrosis by repressing E-cadherin expression.

Sun S, Sun W, Xia L, Liu L, Du R, He L, Li R, Wang H, Huang C.

Cell Commun Signal. 2014 Nov 30;12:76. doi: 10.1186/s12964-014-0076-4.

20.

Supplemental Content

Support Center